Phenotypes associated with this allele

• Allele Symbol: Tg(Nphs1-Ptgs2)14Rhrs
• Allele Name: transgene insertion 14, Raymond Harris
• Allele ID: MGI:5301702
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
tg1	Tg(Nphs1-Ptgs2)14Rhrs/0	involves: C57BL/6 * DBA/2	MGI:5304678

Genotype
MGI:5304678

tg1

• Allelic Composition: Tg(Nphs1-Ptgs2)14Rhrs/0
• Genetic Background: involves: C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

albuminuria ( J:148158 , J:179350 )

• mutants treated with Adriamycin to induce podocyte injury exhibit albuminuria not seen in similarly treated controls; albuminuria is still present in mutants at 10 weeks after injection (J:148158)

• mutants with streptozotocin-induced diabetes exhibit a greater albuminuria than controls with induced diabetes after 16 weeks of diabetes (J:179350)

increased susceptibility to injury ( J:148158 )

• podocytes are more susceptible Adriamycin induced injury compared to controls, showing increased food process effacement, mesangial sclerosis and albuminuria

renal/urinary system

albuminuria ( J:148158 , J:179350 )

• mutants treated with Adriamycin to induce podocyte injury exhibit albuminuria not seen in similarly treated controls; albuminuria is still present in mutants at 10 weeks after injection (J:148158)

• mutants with streptozotocin-induced diabetes exhibit a greater albuminuria than controls with induced diabetes after 16 weeks of diabetes (J:179350)

abnormal podocyte morphology ( J:179350 )

• differentiated podocytes from mutant mice exposed to high-glucose medium exhibit more cytoskeleton disorganization and increased apoptosis compared to similarly treated wild-type podocytes, indicating more severe podocyte injury in mutants

podocyte foot process effacement ( J:148158 , J:179350 )

• untreated mutants exhibit modest foot process effacement (J:148158)

• Adriamycin-treated mutants exhibit increased foot process effacement compared to treated controls (J:148158)

• mutants with streptozotocin-induced diabetes exhibit a significant increase in foot process effacement compared to diabetic controls (J:179350)

increased renal glomerulus basement membrane thickness ( J:179350 )

• mutants with streptozotocin-induced diabetes exhibit increased segmental glomerulus basement membrane thickness compared with no increase in glomerulus basement thickness in diabetic controls

abnormal glomerular mesangium morphology ( J:148158 , J:179350 )

• Adriamycin-treated mutants exhibit mild mesangial sclerosis compared to treated controls (J:148158)

• mutants with streptozotocin-induced diabetes exhibit moderate mesangial expansion compared with minimal mesangial expansion in diabetic controls (J:179350)